Here are the 10-K annual reports from Kalaris Therapeutics, Inc. (KLRS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow KLRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KLRS filings page.
Kalaris Therapeutics, Inc., formerly AlloVir, has transformed into a clinical-stage biopharmaceutical company focused on prevalent retinal diseases after completing a merger with Legacy Kalaris on March 18, 2025. The company’s strategy centers on TH103, a novel anti‑VEGF fusion protein engineered for extended intraocular retention via high‑affinity binding to VEGF and heparan sulfate proteoglycans.
Initial Phase 1a data in neovascular age‑related macular degeneration showed a mean 10‑letter gain in visual acuity and strong fluid resolution after a single dose, with TH103 generally well tolerated aside from some intraocular inflammation that the company is addressing through manufacturing process refinements to lower host cell proteins. A Phase 1b/2 multiple‑dose study in nAMD is ongoing, with preliminary data expected in the first half of 2027, and Kalaris plans potential Phase 3 trials by year‑end 2027 plus indication expansion into diabetic eye disease, retinal vein occlusion and retinopathy of prematurity. The company reports an aggregate market value of non‑affiliate equity of $12.6 million as of June 30, 2025 and 22,928,303 common shares outstanding as of March 10, 2026, and highlights typical early‑stage biotech risks, including continued losses, substantial funding needs, heavy dependence on TH103 and Nasdaq “controlled company” status due to principal stockholder Samsara BioCapital.